104 related articles for article (PubMed ID: 1580288)
1. Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension.
Jandrain B; Herbaut C; Depoorter JC; Voorde KV
Am J Med; 1992 Apr; 92(4B):91S-94S. PubMed ID: 1580288
[TBL] [Abstract][Full Text] [Related]
2. Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Hermans MP; Brichard SM; Colin I; Borgies P; Ketelslegers JM; Lambert AE
Am J Med; 1992 Apr; 92(4B):102S-107S. PubMed ID: 1580274
[TBL] [Abstract][Full Text] [Related]
3. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients.
Bak JF; Gerdes LU; Sørensen NS; Pedersen O
Am J Med; 1992 Apr; 92(4B):69S-72S. PubMed ID: 1580283
[TBL] [Abstract][Full Text] [Related]
4. [Long-term decrease of microalbuminuria after one year of treatment with perindopril in hypertensive diabetic patients].
Brichard SM; Santoni JP; Thomas JR; Van de Voorde K; Ketelslegers JM; Lambert AE
Ann Cardiol Angeiol (Paris); 1990 Oct; 39(8):495-9. PubMed ID: 2281920
[TBL] [Abstract][Full Text] [Related]
5. Renal function, glycemic control and perindopril in diabetic patients.
Brichard S; Ketelslegers JM; Lambert AE
Clin Exp Hypertens A; 1989; 11 Suppl 2():545-54. PubMed ID: 2691128
[TBL] [Abstract][Full Text] [Related]
6. Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Brichard SM; Santoni JP; Thomas JR; van de Voorde K; Ketelslegers JM; Lambert AE
Diabete Metab; 1990; 16(1):30-6. PubMed ID: 2185055
[TBL] [Abstract][Full Text] [Related]
7. Effects of perindopril on serum lipids in hypertensive patients with hyperlipidemia.
Middeke M; Krone W
J Cardiovasc Pharmacol; 1994 Apr; 23(4):629-31. PubMed ID: 7516014
[TBL] [Abstract][Full Text] [Related]
8. Perindopril safety and tolerance in at-risk patients.
Brichard S; Lambert AE
Drugs; 1990; 39 Suppl 1():64-70. PubMed ID: 2407494
[TBL] [Abstract][Full Text] [Related]
9. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
Böhlen L; Bienz R; Doser M; Papiri M; Shaw S; Riesen W; Weidmann P
J Cardiovasc Pharmacol; 1996 Jun; 27(6):770-6. PubMed ID: 8761842
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients.
Suraniti S; Berrut G; Marre M; Fressinaud P
Am J Cardiol; 1993 Jun; 71(17):28E-31E. PubMed ID: 8328364
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Morgan TO; Louis WJ; MacDonald GJ; Conway EL; Bartholomeusz LC; Anderson AI; Cameron DP; Donnelly T; Frewin DB; Hooper MJ
Am J Med; 1992 Apr; 92(4B):73S-78S. PubMed ID: 1580284
[TBL] [Abstract][Full Text] [Related]
12. Long-term acceptability of perindopril: European multicenter trial on 856 patients.
Degaute JP; Leeman M; Desche P
Am J Med; 1992 Apr; 92(4B):84S-90S. PubMed ID: 1580287
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension.
Oksa A; Gajdos M; Fedelesová V; Spustová V; Dzúrik R
J Cardiovasc Pharmacol; 1994 Jan; 23(1):79-86. PubMed ID: 7511740
[TBL] [Abstract][Full Text] [Related]
14. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS).
Stumpe KO; Overlack A
Am J Cardiol; 1993 Jun; 71(17):32E-37E. PubMed ID: 8328365
[TBL] [Abstract][Full Text] [Related]
15. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives.
Tropeano AI; Boutouyrie P; Pannier B; Joannides R; Balkestein E; Katsahian S; Laloux B; Thuillez C; Struijker-Boudier H; Laurent S
Hypertension; 2006 Jul; 48(1):80-6. PubMed ID: 16702490
[TBL] [Abstract][Full Text] [Related]
16. Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril.
Forette F; McClaran J; Delesalle MC; Hervy MP; Bouchacourt P; Henry-Amar M; Santoni JP
Clin Exp Hypertens A; 1989; 11 Suppl 2():587-603. PubMed ID: 2691131
[TBL] [Abstract][Full Text] [Related]
17. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
Giugliano D; Marfella R; Acampora R; Giunta R; Coppola L; D'Onofrio F
Diabetes Care; 1998 Apr; 21(4):631-6. PubMed ID: 9571355
[TBL] [Abstract][Full Text] [Related]
18. Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy.
Duggan KA; Hodge G; Makarious MM; Charlesworth JA
Clin Exp Pharmacol Physiol; 1996; 23(6-7):608-10. PubMed ID: 8800600
[TBL] [Abstract][Full Text] [Related]
19. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group.
BMJ; 1991 Jan; 302(6770):210-6. PubMed ID: 1998761
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerance of perindopril in hypertensive patients with impaired renal function.
Dratwa M; Sennesael J; Taillard F; Baguet F; Suc JM; Lins RL; Lameire N
J Cardiovasc Pharmacol; 1991; 18 Suppl 7():S40-4. PubMed ID: 1725201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
